Home  |  Contact

Cellosaurus P3HR-1 (CVCL_2676)

[Text version]

Cell line name P3HR-1
Synonyms P 3 HR 1; P3HR1; P3HRI; P3HR1-BL; P3J HR-1; P3J-HR-1; P3JHR-1; P3JHR1; P3J HR1-K; P3J.HR1K; HR-1; HR1K; PO
Accession CVCL_2676
Resource Identification Initiative To cite this cell line use: P3HR-1 (RRID:CVCL_2676)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: MD Anderson Cell Lines Project.
Part of: MYC genetic alteration cell panel (ATCC TCP-1035).
Population: African; Nigerian.
Doubling time: 17 hours (PubMed=8402660).
Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Omics: Virome analysis using RNAseq.
Derived from sampling site: Ascites.
Sequence variations Mutation; HGNC; 7553; MYC; Simple; p.Pro72Ser (c.214C>T); ClinVar=VCV000012574; Zygosity=Unspecified (PubMed=8108117).
Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=12068308).
Mutation; HGNC; 11998; TP53; Simple; p.Tyr163His (c.487T>C); ClinVar=VCV000376680; Zygosity=Unspecified (PubMed=2052620; PubMed=8344493; PubMed=8402660).
Mutation; HGNC; 11998; TP53; Simple; p.Glu287Ter (c.859G>T); Zygosity=Unspecified (PubMed=2052620; PubMed=8344493; PubMed=8402660).
HLA typing Source: CLS
Class I
HLA-AA*03:01:01,74:01:01
HLA-BB*53:01:01,58:01:01
HLA-CC*04:01:01
Class II
HLA-DPDPB1*01:01:01,02:01:02
HLA-DQDQA1*01:02:01,05:05:01
DQB1*03:19:01,06:02:01
HLA-DRDRB1*11:02:01,15:03:01
Genome ancestry Source: PubMed=30894373

Origin% genome
African97.8
Native American0
East Asian, North0.68
East Asian, South0
South Asian0
European, North0
European, South1.51
Disease EBV-related Burkitt lymphoma (NCIt: C27694)
Burkitt lymphoma (ORDO: Orphanet_543)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_1317 (Jiyoye)
Children:
CVCL_X203 (D98/HR-1)CVCL_IU56 (FF452-3)CVCL_IU57 (GG618-13)
CVCL_W740 (HH514-16)CVCL_W741 (HH543-5)CVCL_B066 (P3H3)
CVCL_ZI14 (PICAT)CVCL_ZI15 (PICATPO-1)CVCL_ZI12 (PUT)
CVCL_8428 (TDL-1)CVCL_8429 (TDL-2)
Sex of cell Male
Age at sampling 7Y
Category Cancer cell line
STR profile Source(s): ATCC; CLS; ECACC

Markers:
AmelogeninX (CLS; ECACC)
X,Y (ATCC)
CSF1PO10,11
D2S133821
D3S135816,17
D5S81812
D7S8208,10
D8S117914,15
D13S31712
D16S53910,11
D18S5112,19
D19S43312,15
D21S1128,36
FGA23,24
TH017,9
TPOX6,8
vWA15,18,19 (CLS)
15,19 (ATCC; ECACC)

Run an STR similarity search on this cell line
Web pages https://tcpaportal.org/mclp/
Publications

PubMed=4912237; DOI=10.1128/JVI.1.5.1045-1051.1967
Hinuma Y., Konn M., Yamaguchi J., Wudarski D.J., Blakeslee J.R. Jr., Grace J.T. Jr.
Immunofluorescence and herpes-type virus particles in the P3HR-1 Burkitt lymphoma cell line.
J. Virol. 1:1045-1051(1967)

PubMed=4321017; DOI=10.1002/ijc.2910060315
Durr F.E., Monroe J.H., Schmitter R., Traul K.A., Hirshaut Y.
Studies on the infectivity and cytopathology of Epstein-Barr virus in human lymphoblastoid cells.
Int. J. Cancer 6:436-449(1970)

PubMed=4321974
Maurer B.A., Wilbert S.M., Imamura T.
Incidence of EB virus-containing cells in primary and secondary clones of several Burkitt lymphoma cell lines.
Cancer Res. 30:2870-2875(1970)

PubMed=4932228; DOI=10.1002/ijc.2910070214
Gergely L., Klein G., Ernberg I.
The action of DNA antagonists on Epstein-Barr virus (EBV)-associated early antigen (EA) in Burkitt lymphoma lines.
Int. J. Cancer 7:293-302(1971)

PubMed=4115493
Petit P., Verhest A., Lecluse van der Bilt F.A., Jongsma A.P.M.
The chromosomes of the EB virus-positive Burkitt cell line P3J.HR1K studied by the fluorescent staining technique.
Pathol. Eur. 7:17-21(1972)

PubMed=4122458; DOI=10.1002/ijc.2910100108
Klein G., Dombos L., Gothoskar B.
Sensitivity of Epstein-Barr virus (EBV) producer and non-producer human lymphoblastoid cell lines to superinfection with EB-virus.
Int. J. Cancer 10:44-57(1972)

PubMed=4364259; DOI=10.1002/ijc.2910110210
Klein G., Dombos L.
Relationship between the sensitivity of EBV-carrying lymphoblastoid lines to superinfection and the inducibility of the resident viral genome.
Int. J. Cancer 11:327-337(1973)

PubMed=170370; DOI=10.1099/0022-1317-28-2-207
Adams A., Strander H., Cantell K.
Sensitivity of the Epstein-Barr virus transformed human lymphoid cell lines to interferon.
J. Gen. Virol. 28:207-217(1975)

PubMed=327080; DOI=10.1093/jnci/59.1.221
Fogh J., Fogh J.M., Orfeo T.
One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.
J. Natl. Cancer Inst. 59:221-226(1977)

PubMed=913957; DOI=10.20772/cancersci1959.68.3_357
Inada T., Kasuga T., Nojiri I., Hiraoka T., Furuse T.
Comparative study on radiosensitivities of cultured cell lines derived from several human tumors under hypoxic condition.
Gann 68:357-362(1977)

PubMed=6265077
Pizzo P.A., Chattopadhyay S.K., Magrath I.T., Del Giacco E., Sherrick D., Gray T.
Examination of Epstein-Barr virus and C-type proviral sequences in American and African lymphomas and derivative cell lines.
Cancer Res. 41:3165-3171(1981)

PubMed=6278187; DOI=10.1093/jnci/68.2.179
Zeuthen J., Klein G., Ber R., Masucci G., Bisballe S., Povey S., Terasaki P., Ralph P.
Human lymphoma-lymphoma hybrids and lymphoma-leukemia hybrids. I Isolation, characterization, cell surface markers, and B-cell markers.
J. Natl. Cancer Inst. 68:179-195(1982)

PubMed=6278188; DOI=10.1093/jnci/68.2.197
Klein G., Zeuthen J., Ber R., Ernberg I.
Human lymphoma-lymphoma hybrids and lymphoma-leukemia hybrids. II Epstein-Barr virus induction patterns.
J. Natl. Cancer Inst. 68:197-202(1982)

PubMed=6286763
Benjamin D., Magrath I.T., Maguire R.T., Janus C., Todd H.D., Parsons R.G.
Immunoglobulin secretion by cell lines derived from African and American undifferentiated lymphomas of Burkitt's and non-Burkitt's type.
J. Immunol. 129:1336-1342(1982)

PubMed=6231253; DOI=10.1002/ijc.2910330407
Ehlin-Henriksson B., Klein G.
Distinction between Burkitt lymphoma subgroups by monoclonal antibodies: relationships between antigen expression and type of chromosomal translocation.
Int. J. Cancer 33:459-463(1984)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=2140233; DOI=10.1111/j.1440-1827.1990.tb01549.x
Nakano A., Harada T., Morikawa S., Kato Y.
Expression of leukocyte common antigen (CD45) on various human leukemia/lymphoma cell lines.
Acta Pathol. Jpn. 40:107-115(1990)

PubMed=1915267; DOI=10.1002/j.1460-2075.1991.tb07837.x
Farrell P.J., Allan G.J., Shanahan F., Vousden K.H., Crook T.
p53 is frequently mutated in Burkitt's lymphoma cell lines.
EMBO J. 10:2879-2887(1991)

PubMed=2052620; DOI=10.1073/pnas.88.12.5413
Gaidano G., Ballerini P., Gong J.Z., Inghirami G., Neri A., Newcomb E.W., Magrath I.T., Knowles D.M., Dalla-Favera R.
p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia.
Proc. Natl. Acad. Sci. U.S.A. 88:5413-5417(1991)

PubMed=8344493; DOI=10.1096/fasebj.7.10.8344493
Bhatia K.G., Goldschmidts W., Gutierrez M.I., Gaidano G., Dalla-Favera R., Magrath I.T.
Hemi- or homozygosity: a requirement for some but not other p53 mutant proteins to accumulate and exert a pathogenetic effect.
FASEB J. 7:951-956(1993)

PubMed=8402660
O'Connor P.M., Jackman J., Jondle D., Bhatia K.G., Magrath I.T., Kohn K.W.
Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines.
Cancer Res. 53:4776-4780(1993)

PubMed=8108117
Albert T., Urlbauer B., Kohlhuber F., Hammersen B., Eick D.
Ongoing mutations in the N-terminal domain of c-Myc affect transactivation in Burkitt's lymphoma cell lines.
Oncogene 9:759-763(1994)

PubMed=12068308; DOI=10.1038/nature00766
Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
Mutations of the BRAF gene in human cancer.
Nature 417:949-954(2002)

PubMed=12967475; DOI=10.1111/j.1349-7006.2003.tb01518.x
Maesako Y., Uchiyama T., Ohno H.
Comparison of gene expression profiles of lymphoma cell lines from transformed follicular lymphoma, Burkitt's lymphoma and de novo diffuse large B-cell lymphoma.
Cancer Sci. 94:774-781(2003)

PubMed=19358282; DOI=10.1002/ijc.24351
Inagaki A., Ishida T., Yano H., Ishii T., Kusumoto S., Ito A., Ri M., Mori F., Ding J., Komatsu H., Iida S., Ueda R.
Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC.
Int. J. Cancer 125:212-221(2009)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=25355872; DOI=10.1128/JVI.02570-14
Cao S.-B., Strong M.J., Wang X., Moss W.N., Concha M., Lin Z., O'Grady T., Baddoo M., Fewell C., Renne R., Flemington E.K.
High-throughput RNA sequencing-based virome analysis of 50 lymphoma cell lines from the Cancer Cell Line Encyclopedia project.
J. Virol. 89:713-729(2015)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=30285677; DOI=10.1186/s12885-018-4840-5
Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X., Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H., Koeffler H.P.
Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.
BMC Cancer 18:940.1-940.13(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

Cross-references
Cell line collections ATCC; HTB-62
BCRJ; 0338
CLS; 302010/p32722_P3HR1
ECACC; 86010701
IZSLER; BS TCL 99
Cell line databases/resources CLDB; cl3837
CLDB; cl5159
CLDB; cl5242
CCLE; P3HR1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
Cell_Model_Passport; SIDM01254
CGH-DB; 9199-4
DepMap; ACH-000707
IGRhCellID; P3HR1
LINCS_LDP; LCL-2024
Ontologies CLO; CLO_0008282
CLO; CLO_0008331
EFO; EFO_0002312
Biological sample resources BioSample; SAMN10987599
Chemistry resources ChEMBL-Cells; CHEMBL3307242
ChEMBL-Targets; CHEMBL612705
GDSC; 1330988
PharmacoDB; P3HR1_1234_2019
Gene expression databases ArrayExpress; E-MTAB-38
ArrayExpress; E-MTAB-2770
GEO; GSM887493
GEO; GSM888575
Other Wikidata; Q54937282
Polymorphism and mutation databases Cosmic; 724830
Cosmic; 1517661
Cosmic; 2822951
IARC_TP53; 177
LiGeA; CCLE_098
Progenetix; CVCL_2676
Entry history
Entry creation04-Apr-2012
Last entry update20-May-2021
Version number31